Biological E, Dynavax ink commercial supply agreement

Hyderabad vaccine maker to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E’s Covid-19 vaccine candidate Corbevax

Hyderabad: Hyderabad-based Biological E (BE) and Dynavax Technologies Corporation entered into a commercial supply agreement of Dynavax’s CpG 1018 advanced adjuvant, for use in BE’s subunit Covid-19 vaccine candidate, Corbevax.

The commercial supply agreement extends through 2022 and includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax.

---

Pending conditional regulatory approvals in India, BE expects to commence product launch of Corbevax later this year, the company said.

“We believe Corbevax will play a critical role in eradicating the global pandemic,” said Mahima Datla, MD, Biological E.

Last month, the Union Ministry of Health announced that it had finalised arrangements with BE to reserve 300 million doses of Corbevax to be manufactured later this year. The arrangement with BE is part of the wider endeavour from the Government of India to encourage indigenous vaccine manufacturers by providing financial support.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .